Analysis of Both Sex and Device Specific Factors on Outcomes in Patients with Non-Ischemic Cardiomyopathy

NCT ID: NCT03884608

Last Updated: 2024-11-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

1000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-05-09

Study Completion Date

2024-11-19

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this registry is to prospectively assess outcomes of device-treated ventricular tachyarrhythmias and all-cause mortality in non-ischemic cardiomyopathy patients indicated for ICD or CRT-D implantation for the primary prevention of sudden cardiac death. Differences in outcomes will be evaluated by sex and by device type.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The BIO-LIBRA Study will gather information about women and men with non-ischemic cardiomyopathy who are treated with implanted ICD and CRT-D devices from many locations across the United States. The BIO-LIBRA Study will look at the results of treatment in women and men enrollees. The two primary goals are: 1) to learn if there are differences in treatment response based on the patient's sex; and 2) to learn if there are differences in patient outcomes based on device type.

There is a special focus on women in the BIO-LIBRA Study. Usually, only about 25% of people in prior device studies have been women. Yet heart disease is the number-one cause of death for women - one in three deaths each year. The BIO-LIBRA Study would like to have a more balanced study which includes more women than in prior studies. The goal is for at least 40% of the people participating in the study to be women.

The study will observe up to 1,000 women and men over a three-year period following the device implant. Utilizing information collected at annual doctor visits and scheduled transmission reports from the implanted device in between these visits, the BIO-LIBRA Study will be able to evaluate some of the common risks of non-ischemic cardiomyopathy.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cardiomyopathies Gender Implantable Defibrillator User

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patient meets current guideline-defined indication for de novo, primary prevention ICD or CRT-D implantation
2. Patient has non-ischemic etiology of cardiomyopathy
3. Patient is successfully implanted with a de novo BIOTRONIK ICD or CRT-D device and commercially available leads no more than 30 days prior to consent or is scheduled for de novo implantation of a BIOTRONIK ICD or CRT-D device no more than 30 days post consent
4. Patient is able to understand the nature of the study and provide informed consent
5. Patient is available for standard of care follow-up visits to occur at least yearly at the study site for to the expected 3 years of follow-up
6. Patient is willing to utilize BIOTRONIK Home Monitoring® via CardioMessenger
7. Patient age is greater than or equal to 18 years

Exclusion Criteria

1. Patient meets secondary prevention ICD indication
2. Patient has ischemic etiology of cardiomyopathy
3. Patient is enrolled in any investigational cardiac device or drug trial that might significantly affect the studied outcomes
4. Patient is expected to receive heart transplantation or ventricular assist device within 1 year
5. Patient life expectancy is less than 1 year
6. Patient reports pregnancy at the time of consent
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Rochester

OTHER

Sponsor Role collaborator

Biotronik, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Valentina Kutyifa, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

University of Rochester

Jeanne Poole, MD

Role: PRINCIPAL_INVESTIGATOR

University of Washington

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Southview Cardiovascular Associates

Birmingham, Alabama, United States

Site Status

Cardiology Associates of Mobile

Fairhope, Alabama, United States

Site Status

Eisenhower Desert Cardiology

Rancho Mirage, California, United States

Site Status

UC Davis Medical Center

Sacramento, California, United States

Site Status

Cardiology Associates Medical Group

Ventura, California, United States

Site Status

Cardiovascular Institute of North Colorado

Greeley, Colorado, United States

Site Status

University of Florida

Gainesville, Florida, United States

Site Status

AdventHealth Orlando

Orlando, Florida, United States

Site Status

Orlando Health, Inc.

Orlando, Florida, United States

Site Status

BayCare Medical Group Cardiology

Safety Harbor, Florida, United States

Site Status

AdventHealth Tampa

Tampa, Florida, United States

Site Status

Saint Alphonsus Heart Care

Boise, Idaho, United States

Site Status

University of Chicago

Chicago, Illinois, United States

Site Status

University of Iowa

Iowa City, Iowa, United States

Site Status

Baptist Health Lexington

Lexington, Kentucky, United States

Site Status

University of Kentucky

Lexington, Kentucky, United States

Site Status

Massachusetts General Hospital

Boston, Massachusetts, United States

Site Status

University of Michigan

Ann Arbor, Michigan, United States

Site Status

Traverse Heart and Vascular

Traverse City, Michigan, United States

Site Status

Metro Health Hospital

Wyoming, Michigan, United States

Site Status

Michigan Heart

Ypsilanti, Michigan, United States

Site Status

Cardiology Associates Research

Tupelo, Mississippi, United States

Site Status

Mercy Clinic Heart and Vascular

St Louis, Missouri, United States

Site Status

Logan Health Research

Kalispell, Montana, United States

Site Status

NYP Brooklyn Methodist Hospital

Brooklyn, New York, United States

Site Status

Trinity Medical WNY

Buffalo, New York, United States

Site Status

Weill Cornell Medicine

New York, New York, United States

Site Status

Lenox Hill Hospital

New York, New York, United States

Site Status

University of Rochester

Rochester, New York, United States

Site Status

Montefiore Medical Center

The Bronx, New York, United States

Site Status

Westchester Medical Center

Valhalla, New York, United States

Site Status

Sanger Heart and Vascular

Charlotte, North Carolina, United States

Site Status

East Carolina University Physicians

Greenville, North Carolina, United States

Site Status

Heart Rhythm Associates

Greenville, North Carolina, United States

Site Status

Cape Fear Heart Associates

Wilmington, North Carolina, United States

Site Status

Novant Health Winston Salem Cardiology

Winston-Salem, North Carolina, United States

Site Status

Wake Forest Baptist Health

Winston-Salem, North Carolina, United States

Site Status

Sanford Medical Center

Fargo, North Dakota, United States

Site Status

University of Cincinnati

Cincinnati, Ohio, United States

Site Status

Ohio State University

Columbus, Ohio, United States

Site Status

ProMedica Physicians Cardiology

Toledo, Ohio, United States

Site Status

Penn State Health Milton S Hershey

Hershey, Pennsylvania, United States

Site Status

Geisinger Heart and Vascular Center

Scranton, Pennsylvania, United States

Site Status

Upstate Cardiology

Greenville, South Carolina, United States

Site Status

Carolina Heart Specialists

Lancaster, South Carolina, United States

Site Status

Carolina Arrhythmia Consultants

Mt. Pleasant, South Carolina, United States

Site Status

Cardiology Consultants

Spartanburg, South Carolina, United States

Site Status

University of Tennessee Erlanger Cardiology

Chattanooga, Tennessee, United States

Site Status

University of Washington

Seattle, Washington, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Kutyifa V, Di Biase L, Prasad KV, Torres V, Hesselson A, McCotter CJ, Harris G, Cox K, Schleede S, Heist EK, McNitt S, Brown MW, Miller C, Beck CA, Poole J; BIO-LIBRA Investigators. Contemporary medical therapy, sex-specific characteristics, and outcomes of patients with non-ischemic cardiomyopathy: a prespecified interim analysis of the BIO-LIBRA study. EClinicalMedicine. 2025 Jul 13;86:103337. doi: 10.1016/j.eclinm.2025.103337. eCollection 2025 Aug.

Reference Type DERIVED
PMID: 40697957 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

BIO-LIBRA

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.